Healthcare / Medical Instruments & SuppliesNasdaqGS
$20.19
-1.07 (-5.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-85.1M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.4%
↓Gross Margin
40.5%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+180.0%
FCF CAGR
—
FCF margin
-169.2%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $59.8M · net income $-113.8M · FCF $-101.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $59.8M | $59.8M | $27.8M | $7.6M |
| Net Income | $-113.8M | $-113.8M | $-94.1M | $-84.2M |
| EBITDA | $-98.0M | $-98.0M | $-76.3M | $-73.7M |
| EPS | -5.13 | -5.13 | -5.07 | -4.36 |
| Gross Margin | 40.5% | 40.5% | 1.3% | -139.6% |
| Operating Margin | -177.8% | -177.8% | -305.8% | -1054.0% |
| Net Margin | -190.3% | -190.3% | -338.4% | -1104.0% |
| Balance Sheet | ||||
| Debt/Equity | 0.22 | 0.22 | -0.22 | -0.33 |
| Current Ratio | 7.32 | 7.32 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-101.2M | $-101.2M | $-84.7M | $-85.1M |
| Returns | ||||
| ROE | -55.4% | -55.4% | 45.0% | 71.6% |
| Valuation | ||||
| P/B | 2.42 | 2.42 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 115.1% | 115.1% | 264.5% | — |
| EPS Growth | -1.2% | -1.2% | -16.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.07 → -5.13
Residual
-10.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.